Real-World Effectiveness of Tildrakizumab in Japanese Patients With Psoriasis: Analyses Stratified by Prior Systemic Therapy, Maintenance of Early Responses, and Achievement of Delayed Responses
{{output}}
There are no real-world studies on the long-term effectiveness of anti-interleukin-23 antibody tildrakizumab in Japanese patients with psoriasis stratified by pretreatment status. To evaluate the 52-week real-world effectiveness of tildrakizumab for psoriasis ... ...
